AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY

氨基胍在患有明显糖尿病肾病的糖尿病患者中的应用

• 批准号: 6278856
• 负责人: G APPEL
• 金额: $ 2.3万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278856
• 关键词: adrenal disorder; aminoguanidine; clinical research; clinical trials; diabetes mellitus therapy; diabetic nephropathy; diabetic retinopathy; drug screening /evaluation; human subject; human therapy evaluation; kidney disorder chemotherapy; pathologic process; placebos

A placebo controlled study of Aminoguanidine in patients with diabetic Nephropathy to see whether the agent is effective in slowing the progression of renal disease in diabetics. Secondary endpoints will include the study of the effect of diabetic retinopathy.

氨基胍治疗糖尿病的安慰剂对照研究 肾病，看看该药是否有效地减缓了 糖尿病患者肾脏疾病的进展。次要终端将 包括对糖尿病视网膜病变影响的研究。